top of page
Building a diversified biotech portfolio of CAR
T-cell therapies.


Wellington Zhaotai Therapies is the global (excluding Greater China) commercialisation entity for Hunan Medical Group's and the Malaghan Institute of Medical Research's CAR T- cell therapies.

Combined, Wellington Zhaotai Therapies has more than 130 hundred employees engaged in biotechnology research and technology and clinical trials. 

Highlights of our cell therapy capabilities


  • CAR T–cell therapy Phase I trials targeting B-ALL lymphoma, lung cancer, liver cancer, pancreatic cancer, gastric cancer with nine construct designs being trialled (China).

  • Multiple pre-clinical china trials in B-ALL lymphoma, multiple myeloma and acute myeloid leukaemia (China).

  • CAR T–cell therapy Phase I trials targeting non Hodgkin Lymphoma (New Zealand).

  • GMP facilities for viral construct and biopharmaceutical manufacture (China, New Zealand).

bottom of page